AzTrials
AzTrials

Covid-19NCT04407585

Testing the Accuracy of a Digital Test to Diagnose Covid-19

An observational study of Covid-19, run by King's College London at 1 site in United Kingdom.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The Covid-19 viral pandemic has caused significant global losses and disruption to all aspects of society. One of the major difficulties in controlling the spread of this coronavirus has been the delayed and mild (or lack of) presentation of symptoms in infected individuals, and the insufficient Covid-19 testing… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Covid-19
What is being tested?
Covid-19 swab PCR test
How many people
1,000,000 participants
Where
1 siteUnited Kingdom
Study dates
1 Jun 2020to 10 May 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: The study population includes individuals are UK-based primary users of the Covid Symptom Study app, who provide informed consent to participate.

Study Inclusion Criteria - app users will be eligible to join the study if they:

  • Are based in the UK (are using the UK version of the Covid-19 Symptom Study app, and have listed a UK postcode)
  • Are the primary app user (are reporting directly for themselves)
  • Are at least 18 years of age
  • Have not tested positive for a Covid-19 test before (but may have been tested)

Study Exclusion Criteria - participants are ineligible for the study if they:

  • Do not meet inclusion criteria
  • Do not provide informed consent to participate

Participants will be subject to further screening to identify them as eligible for swab testing during the course of the study.

Swab inclusion criteria - participants will be eligible for swab testing if they:

  • Have reported in the app at least once in the previous 3 days (days -2 to 0), and at least two times in the previous 9 days (days -8 to 0). All reports must be healthy (i.e. not experiencing any symptoms).
  • On the previous day (day 1), have reported that they are experiencing at least one symptom described in the app. Symptoms in the app are updated when deemed appropriate by study investigators using evidence based reports in the scientific and medical field.
  • Have answered the phenotype fields required for the prediction model with physiologically plausible values.

Swab exclusion criteria - participants are ineligible for swab testing if they:

  • Are asymptomatic
  • Do not satisfy the inclusion criteria for testing.

Insufficient testing capacity:

If insufficient testing capacity is available for the study population as described, then recruitment will be prioritised according to:

  • Firstly, most recent final healthy report before reporting symptoms
  • Secondly, highest number of healthy reports during the previous 9 days before reporting symptoms
  • Thirdly, randomised selection to stratify between participants of equal priority according to the first two rules above.

Excess testing capacity:

If excess testing capacity is available beyond the study population as described, then inclusion criteria will be expanded in order to adequately sample across under-represented population groups.

Specifically, on day 7 of each validation phase, investigators will assess:

  • What excess testing capacity is available, if any
  • Which subgroups are under-represented compared to their proportion in the UK population (as best as can be established given that some participants may not have completed some phenotype fields): (i) Age decade (ii) Sex (iii) Ethnicity (iv) BMI category

For underrepresented groups, investigators may additionally recruit participants with only one report during the previous 3 days (days -2 to 0) and no other report during the previous 9 days (days -8 to 0).

Trial locations and contacts

1 site in 1 country.

Inbar Linenberg, MSc contact

+447791871699

inbar.linenberg@kcl.ac.uk

United Kingdom1 site, 1 recruiting
  • King's College London

    London, SE1 9NH

    Inbar Linenberg, MSc, +447791871699, inbar.linenberg@kcl.ac.uk

    Tim Spector

    Recruiting

Other trials in United Kingdom

About this study

Official title: Validation of Machine Learning (ML) Models as Diagnostic Tools to Predict Infection With SARS-CoV-2

The Covid-19 viral pandemic has caused significant global losses and disruption to all aspects of society. One of the major difficulties in controlling the spread of this coronavirus has been the delayed and mild (or lack of) presentation of symptoms in infected individuals, and the insufficient Covid-19 testing capacity in the UK. This warrants the development of alternative diagnostic tools that reliably assess Covid-19 infection in the early stages of infection, while also being low- cost, low-burden, and easily administered to a wide proportion of the population.

This study aims to validate machine learning models as a diagnostic tool that predicts infection with SARS-CoV-2 based on app-reported symptoms and phenotypic data, against the 'gold-standard' swab PCR-test. This study will take place within the Covid Symptom Study app, the free symptom tracking mobile application launched in March 2020.

Read the detailed description

The Covid-19 viral pandemic has caused significant global losses and disruption to all aspects of society (including health, education, and business and economic security). One of the major difficulties in controlling the spread of this coronavirus has been the delayed and mild (or lack of) presentation of symptoms in infected individuals. Moreover, there is insufficient Covid-19 testing capacity in the UK, and only moderate accuracy of such tests at confirming coronavirus infection. Together, these obstacles have led to countless unknown coronavirus cases going unobserved and fuelling the viral spread in the population, by compromising the stringency of self- isolation measures undertaken by infected individuals who may have otherwise curbed or prevented their transmission of the virus. The profound and widespread cost of the continuing Covid-19 progression, coinciding with the lack of testing capacity, warrants the development of alternative diagnostic tools that reliably assess Covid-19 infection in the early stages of infection, while also being low- cost, low-burden, and easily administered to a wide proportion of the population.

The free symptom-monitoring app 'Covid Symptom Study' was launched in mid-March by health technology start-up Zoe Global Ltd, and is currently being used in the UK, US and Sweden, with more than 2.7 million users in the UK alone who use the app to self-report their Covid-19 symptoms. Upon registering to use the app, users are asked to report demographic and phenotypic data such as age, sex, BMI, ethnicity, contact with infected individuals (through a healthcare professional capacity), smoking behaviour, existing health conditions, among other information. From then on, users are asked to report, on a daily basis, their presentation of symptoms attributable to Covid-19 (or lack thereof) through the use of app-administered questionnaires, thus enabling real-time tracking of disease progression across the UK. The app also allows users to report their Covid-19 test results, thus enabling the development of prediction algorithms based solely on self-reported user data to predict the presence of infection in untested users.

On behalf of Zoe Global Ltd, the UK Department of Health and Social Care with support from the UK's Chief Scientific Advisor has committed to test up to 10,000 app-users per week for infection with SARS-CoV-2 across England and Northern Ireland, for the purpose of rapidly improving the accuracy of symptom-based predictions. Similar testing allowance may follow in Scotland and Wales.

Symptomatic app-users will be asked to get tested for SARS-CoV-2 infection, using the popular swab and qRT-PCR technique, and asked to report their test results in the app, while continuing to log their symptoms.

This validation study, conducted at King's College London, aims to validate the sensitivity and specificity of machine learning models as a diagnostic tool that predicts infection with SARS-CoV-2 based on app-reported symptoms and phenotypic data, against the 'gold-standard' swab PCR-test, by utilising the Covid Symptom Study app as a research platform.

It is hypothesised that by training the symptom-based models using swab test results and through multiple model iterations following continuous data input from reporting and tested app users, predictions of infection will be made with considerable accuracy, thus enabling the Covid Symptom Study app to be used as a diagnostic tool that alleviates the strain of testing capacity in the UK while being easily accessible and posing low user burden.

Study Design:

Due to the rapidly developing and uncertain duration and intensity of the Covid-19 pandemic, the present study design is prospective and one that enables regular iteration on prediction models and continuous accumulation of validation data. The study consists of a series of phases, each lasting 14 days. Before the start of each phase (day 0), a set of machine learning models will be frozen and submitted for validation on data collected during this and subsequent phases.

Machine learning algorithms improve with increasing data. Therefore, validation phases will continue as long as tests are available and app users consent to joining the study. Due to the uncertainty around the progression of UK infection rates, the validation study will be continue whilst it is of value to public health.

A detailed statistical analysis plan is described in the document attached to this record. A record of all machine learning models used for validation will be regularly updated on GitHub (https://github.com/zoe/covid-validation-study).

Conditions
Covid-19
Being tested
Covid-19 swab PCR test
Keywords
Covid-19, Machine learning, Covid-19 diagnostic
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Covid-19 swab PCR testDiagnostic test

    Participants satisfying machine learning test criteria will be asked to take a swab test for Covid-19.

Study groups in NCT04407585
Study groupRoleWhat they receive
Covid-19 Symptom Study app-userUK-based Covid-19 Symptom Study primary app-user completing self-reports in the app
Receives: Diagnostic Test: Covid-19 swab PCR test

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. SARS-CoV-2 infection

    Likelihood of infection with Covid-19, based on app-reported symptoms

    Measured: 3 days

  2. SARS-CoV-2 infection

    Active infection with Covid-19 as assessed by PCR swab test

    Measured: 1 day

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 May 2020
  2. Study start1 Jun 2020
  3. Primary completion10 May 2023 (estimated)
  4. Study completion10 May 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
1,000,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04407585
Sponsor's protocol ID
Covid-19 Validation Study
Status last verified
Mar 2022
First submitted
27 May 2020
Last updated
31 Mar 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Covid-19, run by King's College London at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 31 Mar 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Inbar Linenberg, MSc (+447791871699, inbar.linenberg@kcl.ac.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

SARS-CoV-2 infection (time frame: 3 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Mar 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in